Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
The Prognostic Role Of Circulating Tumour Dna Detected Prior To Clinical Diagnosis Of Colorectal Cancer In The Hunt Study.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
The Prognostic Role Of Circulating Tumour Dna Detected Prior To Clinical Diagnosis Of Colorectal Cancer In The Hunt Study.

Related Experiment Video

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

The prognostic role of circulating tumour DNA detected prior to clinical diagnosis of colorectal cancer in the HUNT study.

Siv Stakset Brenne^1,2, Poul Henning Madsen^3,4, Inge Søkilde Pedersen^3,4,5

¹Department of Surgery, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway. siv.s.brenne@ntnu.no.

|October 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Prediagnostic circulating tumor DNA (ctDNA) markers show promise in predicting poor prognosis for colorectal cancer (CRC). These ctDNA biomarkers could aid in developing personalized treatment strategies for CRC patients.

Keywords:

Circulating tumour DNA Colorectal cancer DNA methylation Liquid biopsy

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

Area of Science:

Oncology
Molecular Diagnostics
Cancer Biomarkers

Background:

Current prognostic tools for colorectal cancer (CRC) at diagnosis are limited, hindering personalized treatment.
There is a need for improved prognostic markers to guide individualized therapeutic approaches in CRC.

Purpose of the Study:

To investigate the predictive value of prediagnostic circulating tumor DNA (ctDNA) markers in plasma for colorectal cancer (CRC) prognosis.
To determine if ctDNA analysis can identify patients with a higher risk of poor outcomes in CRC.

Main Methods:

An observational cohort study involving 85 patients diagnosed with CRC stages I-III within 24 months of the Trøndelag Health Study.
Analysis of known methylated ctDNA biomarkers in plasma using PCR.
Cox regression analysis to identify predictors of overall survival (OS), recurrence-free survival (RFS), and poor prognosis (PP).

Main Results:

Several methylated ctDNA markers, including RARB and WNT5A, were identified as independent predictors of OS, RFS, and PP.
Specific markers like GRIA4, SLC8A1, and VIM also showed significant associations with OS.
SDC2 emerged as a significant predictor for RFS and PP.

Conclusions:

Prediagnostic ctDNA markers are valuable tools for predicting poor prognosis in colorectal cancer.
These findings suggest that ctDNA analysis can contribute to personalized treatment strategies for CRC patients.
Methylated ctDNA biomarkers offer a promising avenue for early risk stratification in CRC.